Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer☆
暂无分享,去创建一个
P. Brown | I. Thompson | H. Parnes | S. Lippman | K. Do | I. Gorlov | Y. Lotan | J. Lee | C. Magi-Galluzzi | E. Klein | P. Troncoso | John W. Davis | C. Logothetis | C. Pettaway | Jeri Kim | L. Pisters | Xuemei Wang | A. Stephenson | E. Efstathiou | J. Ward | L. Vornik | J. Basler | A. Hoque | Elsa M. Li Ning Tapia | Ina N. Prokhorova | J. Lee | I. Thompson
[1] E. Kikuchi,et al. Potent increased risk of the initiation of DNA replication in human prostate cancer with the use of 5α-reductase inhibitors. , 2014, American journal of clinical and experimental urology.
[2] Ian M Thompson,et al. Long-term survival of participants in the prostate cancer prevention trial. , 2013, The New England journal of medicine.
[3] C. Logothetis,et al. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. , 2013, Cancer discovery.
[4] H. Parnes,et al. Prostate cancer prevention: strategies for agent development , 2013, Current opinion in oncology.
[5] P. Troncoso,et al. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers , 2013, The Prostate.
[6] M. Lucia,et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial , 2012, The Lancet.
[7] D. Tsavachidou,et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Mills,et al. Androgen Regulation of 5α-Reductase Isoenzymes in Prostate Cancer: Implications for Prostate Cancer Prevention , 2011, PloS one.
[9] P. Nelson,et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. , 2011, Cancer cell.
[10] I. Leav,et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. , 2010, Cancer cell.
[11] D. Tindall,et al. Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.
[12] R. Ummanni,et al. Immunohistochemical expression of caspase-1 and -9, uncleaved caspase-3 and -6, cleaved caspase-3 and -6 as well as Bcl-2 in benign epithelium and cancer of the prostate. , 2010, Experimental and therapeutic medicine.
[13] M. Shen,et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.
[14] J. Thrasher,et al. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. , 2009, The Journal of urology.
[15] 豊 木村,et al. 胃癌手術におけるCommon Terminology Criteria for Adverse Events v3.0を利用した合併症の評価 , 2009 .
[16] K. Leong,et al. Generation of a prostate from a single adult stem cell , 2008, Nature.
[17] C. K. Too,et al. Levels of 5α-Reductase Type 1 and Type 2 are Increased in Localized High Grade Compared to Low Grade Prostate Cancer , 2008 .
[18] C. K. Too,et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. , 2008, The Journal of urology.
[19] M. Kattan,et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.
[20] D. Bostwick,et al. The effects of the dual 5α‐reductase inhibitor dutasteride on localized prostate cancer—results from a 4‐month pre‐radical prostatectomy study , 2006, The Prostate.
[21] Ximing J. Yang,et al. Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer , 2006, BMC Cancer.
[22] L. Egevad,et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.
[23] D. Troyer,et al. Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer , 2005 .
[24] D. Troyer,et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. , 2005, The Prostate.
[25] M. Gleave,et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. , 2004, The Journal of urology.
[26] W. Gerald,et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. , 2004, Endocrine-related cancer.
[27] Michael M Lieber,et al. Journal Review , 2003, International Society of Hair Restoration Surgery.
[28] R. Lathe,et al. An endocrine pathway in the prostate, ERβ, AR, 5α-androstane-3β,17β-diol, and CYP7B1, regulates prostate growth , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[29] R. Lathe,et al. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.